Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Research article

Competing risk analyses of overall survival and cancer-specific survival in patients with combined hepatocellular cholangiocarcinoma after surgery

Authors: Chaobin He, Yu Zhang, Zhiyuan Cai, Xiaojun Lin

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Our objective was to identify risk factors affecting overall survival (OS) and cancer-specific survival (CSS) and build nomograms to predict survival based on a large population-based cohort.

Methods

Two hundred and thirty patients diagnosed with CHCC between 2004 and 2015 were retrospectively extracted from the Surveillance, Epidemiology, and End Results (SEER) database as a training cohort. In addition, Ninety-nine patients diagnosed with CHCC between 2000 and 2017 were retrospectively extracted from Sun Yat-Sen University Cancer Center (SYSUCC) as an external validation. Nomograms for predicting probability of OS and CSS were established. Performance of the nomograms was measured by concordance index (C-index) and the area under receiver operating characteristic (ROC) curve (AUC).

Results

In training cohort, the 1-, 2 and 3-year OS were 67.7, 46.8 and 37.9%, and the 1-, 2 and 3-year CSS were 73.1, 52.0 and 43.0%, respectively. The established nomograms were well calibrated in both training and validation cohort, with concordance indexes (C-index) of 0.652 and 0.659, respectively for OS prediction; 0.706 and 0.763, respectively for CSS prediction. Nomograms also displayed better discriminatory compared with 8th edition tumor-node-metastasis (TNM) stage system for predicting OS and CSS.

Conclusion

We constructed nomograms to predict OS and CSS based on a relatively large cohort. The established nomograms were well validated and could serve to improve predictions of survival risks and guide management of patients with CHCC after surgery.
Literature
1.
go back to reference Bosman FT. HH: WHO classifcation of tumours of the digestive system, 4th edn. Lyon: International Agency for Research on Cancer; 2010. Bosman FT. HH: WHO classifcation of tumours of the digestive system, 4th edn. Lyon: International Agency for Research on Cancer; 2010.
2.
go back to reference Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract. 2008;62(8):1271–8.CrossRef Kassahun WT, Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract. 2008;62(8):1271–8.CrossRef
3.
go back to reference Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, Zhou Y, Fan J. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol. 2012;19(9):2869–76.CrossRef Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, Zhou Y, Fan J. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol. 2012;19(9):2869–76.CrossRef
4.
go back to reference Yap AQ, Chen CL, Yong CC, Kuo FY, Wang SH, Lin CC, Liu YW, Lin TL, Li WF, Millan CA, et al. Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma. Surg Oncol. 2013;22(1):55–60.CrossRef Yap AQ, Chen CL, Yong CC, Kuo FY, Wang SH, Lin CC, Liu YW, Lin TL, Li WF, Millan CA, et al. Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma. Surg Oncol. 2013;22(1):55–60.CrossRef
6.
go back to reference Xu L, Peng ZW, Chen MS, Shi M, Zhang YJ, Guo RP, Lin XJ, Lau WY. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. J Hepatol. 2015;63(1):122–30.CrossRef Xu L, Peng ZW, Chen MS, Shi M, Zhang YJ, Guo RP, Lin XJ, Lau WY. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. J Hepatol. 2015;63(1):122–30.CrossRef
7.
go back to reference He CB, Lin XJ. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. PLoS One. 2017;12(3):e0174769.CrossRef He CB, Lin XJ. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. PLoS One. 2017;12(3):e0174769.CrossRef
8.
go back to reference He CB, Lao XM, Lin XJ. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chinese J Cancer. 2017;36(1):59.CrossRef He CB, Lao XM, Lin XJ. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chinese J Cancer. 2017;36(1):59.CrossRef
9.
go back to reference He C, Mao Y, Lao X, Li S, Lin X. Neutrophil-to-lymphocyte ratio predicts overall survival of patients with combined hepatocellular cholangiocarcinoma. Oncol Lett. 2018;15(4):4262–8.PubMedPubMedCentral He C, Mao Y, Lao X, Li S, Lin X. Neutrophil-to-lymphocyte ratio predicts overall survival of patients with combined hepatocellular cholangiocarcinoma. Oncol Lett. 2018;15(4):4262–8.PubMedPubMedCentral
10.
go back to reference He C, Mao Y, Wang J, Song Y, Huang X, Lin X, Li S. The predictive value of staging systems and inflammation scores for patients with combined hepatocellular cholangiocarcinoma after surgical resection: a retrospective study. J Gastrointest Surg. 2018;22(7):1239–50.CrossRef He C, Mao Y, Wang J, Song Y, Huang X, Lin X, Li S. The predictive value of staging systems and inflammation scores for patients with combined hepatocellular cholangiocarcinoma after surgical resection: a retrospective study. J Gastrointest Surg. 2018;22(7):1239–50.CrossRef
11.
go back to reference Tian MX, He WJ, Liu WR, Yin JC, Jin L, Tang Z, Jiang XF, Wang H, Zhou PY, Tao CY, et al. A novel risk prediction model for patients with combined hepatocellular-cholangiocarcinoma. J Cancer. 2018;9(6):1025–32.CrossRef Tian MX, He WJ, Liu WR, Yin JC, Jin L, Tang Z, Jiang XF, Wang H, Zhou PY, Tao CY, et al. A novel risk prediction model for patients with combined hepatocellular-cholangiocarcinoma. J Cancer. 2018;9(6):1025–32.CrossRef
12.
go back to reference Kim SH, Park YN, Lim JH, Choi GH, Choi JS, Kim KS. Characteristics of combined hepatocelluar-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2014;40(8):976–81.CrossRef Kim SH, Park YN, Lim JH, Choi GH, Choi JS, Kim KS. Characteristics of combined hepatocelluar-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2014;40(8):976–81.CrossRef
13.
go back to reference Ma MC, Chen YJ, Chiu TJ, Lan J, Liu CT, Chen YC, Tien HH, Chen YY. Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma. BMC Cancer. 2018;18(1):227.CrossRef Ma MC, Chen YJ, Chiu TJ, Lan J, Liu CT, Chen YC, Tien HH, Chen YY. Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma. BMC Cancer. 2018;18(1):227.CrossRef
14.
go back to reference Schiergens TS, Lindenthaler A, Thomas MN, Rentsch M, Mittermeier L, Brand K, Kuchenhoff H, Lee S, Guba M, Werner J, et al. Time-dependent impact of age and comorbidities on long-term overall survival after liver resection. Liver Int. 2016;36(9):1340–50.CrossRef Schiergens TS, Lindenthaler A, Thomas MN, Rentsch M, Mittermeier L, Brand K, Kuchenhoff H, Lee S, Guba M, Werner J, et al. Time-dependent impact of age and comorbidities on long-term overall survival after liver resection. Liver Int. 2016;36(9):1340–50.CrossRef
15.
go back to reference Szpakowski JL, Tucker LY. Causes of death in patients with hepatitis B: a natural history cohort study in the United States. Hepatology (Baltimore, Md). 2013;58(1):21–30.CrossRef Szpakowski JL, Tucker LY. Causes of death in patients with hepatitis B: a natural history cohort study in the United States. Hepatology (Baltimore, Md). 2013;58(1):21–30.CrossRef
16.
go back to reference Shindoh J, Kawamura Y, Kobayashi Y, Kiya Y, Sugawara T, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Platelet-albumin score as a sensitive measure for surgical risk prediction and survival outcomes of patients with hepatocellular carcinoma. J Gastrointest Surg. 2018;23(1):76–83.CrossRef Shindoh J, Kawamura Y, Kobayashi Y, Kiya Y, Sugawara T, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Platelet-albumin score as a sensitive measure for surgical risk prediction and survival outcomes of patients with hepatocellular carcinoma. J Gastrointest Surg. 2018;23(1):76–83.CrossRef
17.
go back to reference Noordzij M, Leffondre K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. 2013;28(11):2670–7.CrossRef Noordzij M, Leffondre K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. 2013;28(11):2670–7.CrossRef
18.
go back to reference Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.CrossRef Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.CrossRef
19.
go back to reference Norris CM, Ghali WA, Saunders LD, Brant R, Galbraith D, Faris P, Knudtson ML. Ordinal regression model and the linear regression model were superior to the logistic regression models. J Clin Epidemiol. 2006;59(5):448–56.CrossRef Norris CM, Ghali WA, Saunders LD, Brant R, Galbraith D, Faris P, Knudtson ML. Ordinal regression model and the linear regression model were superior to the logistic regression models. J Clin Epidemiol. 2006;59(5):448–56.CrossRef
20.
go back to reference Li D, Zhong C, Tang X, Yu L, Ding K, Yuan Y. Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy. J Cancer Res Clin Oncol. 2018;144(5):909–23.CrossRef Li D, Zhong C, Tang X, Yu L, Ding K, Yuan Y. Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy. J Cancer Res Clin Oncol. 2018;144(5):909–23.CrossRef
21.
go back to reference Zhou H, Zhang Y, Qiu Z, Chen G, Hong S, Chen X, Zhang Z, Huang Y, Zhang L. Nomogram to predict cause-specific mortality in patients with surgically resected stage I non-small-cell lung cancer: a competing risk analysis. Clin Lung Cancer. 2018;19(2):e195–203.CrossRef Zhou H, Zhang Y, Qiu Z, Chen G, Hong S, Chen X, Zhang Z, Huang Y, Zhang L. Nomogram to predict cause-specific mortality in patients with surgically resected stage I non-small-cell lung cancer: a competing risk analysis. Clin Lung Cancer. 2018;19(2):e195–203.CrossRef
22.
go back to reference Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepato-Biliary-Pancreat Surg. 2006;13(6):537–42.CrossRef Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepato-Biliary-Pancreat Surg. 2006;13(6):537–42.CrossRef
23.
go back to reference Bergquist JR, Groeschl RT, Ivanics T, Shubert CR, Habermann EB, Kendrick ML, Farnell MB, Nagorney DM, Truty MJ, Smoot RL. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics. HPB (Oxford). 2016;18(11):886–92.CrossRef Bergquist JR, Groeschl RT, Ivanics T, Shubert CR, Habermann EB, Kendrick ML, Farnell MB, Nagorney DM, Truty MJ, Smoot RL. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics. HPB (Oxford). 2016;18(11):886–92.CrossRef
24.
go back to reference Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol. 2017;66(5):952–61.CrossRef Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol. 2017;66(5):952–61.CrossRef
25.
go back to reference Chu KJ, Lu CD, Dong H, Fu XH, Zhang HW, Yao XP. Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases. Eur J Gastroenterol Hepatol. 2014;26(2):192–9.CrossRef Chu KJ, Lu CD, Dong H, Fu XH, Zhang HW, Yao XP. Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases. Eur J Gastroenterol Hepatol. 2014;26(2):192–9.CrossRef
26.
go back to reference Lian M, Perez M, Liu Y, Schootman M, Frisse A, Foldes E, Jeffe DB. Neighborhood socioeconomic deprivation, tumor subtypes, and causes of death after non-metastatic invasive breast cancer diagnosis: a multilevel competing-risk analysis. Breast Cancer Res Treat. 2014;147(3):661–70.CrossRef Lian M, Perez M, Liu Y, Schootman M, Frisse A, Foldes E, Jeffe DB. Neighborhood socioeconomic deprivation, tumor subtypes, and causes of death after non-metastatic invasive breast cancer diagnosis: a multilevel competing-risk analysis. Breast Cancer Res Treat. 2014;147(3):661–70.CrossRef
27.
go back to reference Shin DW, Suh B, Park Y, Lim H, Suh YS, Yun JM, Cho B, Yang HK. Risk of coronary heart disease and ischemic stroke incidence in gastric cancer survivors: a Nationwide study in Korea. Ann Surg Oncol. 2018;25(11):3248–56.CrossRef Shin DW, Suh B, Park Y, Lim H, Suh YS, Yun JM, Cho B, Yang HK. Risk of coronary heart disease and ischemic stroke incidence in gastric cancer survivors: a Nationwide study in Korea. Ann Surg Oncol. 2018;25(11):3248–56.CrossRef
Metadata
Title
Competing risk analyses of overall survival and cancer-specific survival in patients with combined hepatocellular cholangiocarcinoma after surgery
Authors
Chaobin He
Yu Zhang
Zhiyuan Cai
Xiaojun Lin
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5398-6

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine